Table 1. Comparison of baseline characteristics and laboratory between groups

	Group I (n =35)	Group II (n = 69)	P
Age, years	61.3 ± 16.1	60.9 ± 12.2	0.891
Gender, F/M	3/32	3/66	0.402
BMI, kg/m^2	26.2 ± 5.8	24.2 ± 5.5	0.081
SBP, mmHg	121.4 ± 10.5	122.8 ± 9.6	0.521
DBP, mmHg	68.3 ± 9.4	70.8 ± 9.1	0.187
Smoking, pocket/years	35 (20-58)	40 (25-50)	0.297
Urea, mg/dl	32 (26-48)	435 (25-45)	0.972
Creatinine, mg/dl	0.9 ± 0.4	0.8 ± 0.4	0.761
Sodium, mg/dl	138.6 ± 2.6	138.5 ± 3.0	0.878
Potassium, mg/dl	4.4 ± 0.9	4.5 ± 0.4	0.813
AST, U/dL	12 (10-18)	15 (9-21)	0.513
ALT, U/dL	19 (16-24)	19 (12-31)	0.910
WBC, x10^3/mL	10.2 ± 3.4	10.7 ± 3.4	0.544
Hemoglobin, g/dL	14.9 ± 2.1	14.8 ± 2.2	0.769
MCV, fL	88.6 ± 6.5	86.9 ± 7.4	0.266
MPV, fL	7.3 ± 1.2	7.2 ± 1.0	0.589
Platelet, x10^3/mL	291 (237-390)	313 (240-364)	0.926
RDW, %	12.5 ± 1.7	13.3 ± 2.4	0.103

Group I, mild and moderate COPD stages; group II, severe and very severe COPD stages; COPD, chronic obstructive pulmonary disease; F, female, M, male; BMI, body mass index, SBP, systolic blood pressure; DBP, diastolic blood pressure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; WBC, white blood cell; MCV, mean corpuscular volume; MPV, mean platelet volume; RDW, red cell distribution width.

Table 2. Comparison of pulmonary function tests between mild-moderate and severe-very severe COPD groups

	Group I (n =35)	Group II (n = 69)	P
FVC, l,	2.9 (2.0-3.6)	1.8 (1.4-2.2)	<0.001
FEV1, l	1.9 (1.3-2.3)	1.0 (0.7-1.3)	<0.001
FEV1/FVC (%)	67.0 (62.0-69.0)	55.0 (49.5-64.0)	<0.001
MEF25-75, l/sec	1.1 (0.8-1.4)	0.6 (0.4-0.9)	<0.001
DLCO (%)	76.0 (49.8-96.5)	60.0 (47.0-87.0)	0.217
DLCO/VA (%)	81.5 (63.0-116.5)	99.0 (74.0-130.0)	0.407
RV, l	3.0 (2.3-3.5)	2.7 (2.2-3.5)	0.402
TLC, l	5.6 (4.3-6.2)	4.7 (3.7-5.2)	0.003

FEV1, forced expiratory volume in 1 second; FVC = forced vital capacity; MEF25-75, maximum expiratory middle flow rate; DLCO, Carbon monoxide diffusion capacity; DLCO / VA, Carbon monoxide diffusion capacity/alveolar volume; RV, Residual volume; TLC, total lung capacity.

Table 3. Independent predictors of the severe-very severe COPD

	OR	95% CI	P
Frontal QRS-T angle	1.051	1.024-1.079	<0.001

OR: odds ratio, CI: confidence interval

Entered variables: age, gender, body mass index, smoking, creatinine, white blood cell, hemoglobin, platelet, frontal QRS-T angle

Table 4. Independent predictors of the frontal QRS-T angle according to the linear regression analysis.

	Unstandardized coefficients		Standardized coefficients		
	B	SE	β	t	p
Age	–0.263	0.271	–0.135	–0.969	0.336
Gender	31.119	19.052	0.197	1.633	0.108
BMI	–0.451	0.656	–0.099	–0.687	0.495
Smoking,pocket/years	–0.023	0.147	–0.022	–0.157	0.876
WBC	–0.606	–1.151	–0.072	–0.526	0.601
Hemoglobin	1.473	1.546	0.121	0.953	0.345
Platelet	0.005	0.033	0.021	0.165	0.870
FEV1/FVC	0.010	0.301	0.005	0.034	0.973
MEF25-75	–36.201	12.733	–0.593	–2.843	0.006
DLCO/VA	–0.073	0.148	–0.076	–0.496	0.622
RV	–4.968	7.386	–0.169	–0.673	0.504
TLC	4.407	6.901	0.192	0.639	0.526

B: Unstandardized regression coefficient; SE: Standard error; β: Standardized β coefficient.

BMI, body mass index; WBC, white blood cell; FEV1/FVC, forced expiratory volume in 1 second to forced vital capacity; MEF25-75, maximum expiratory middle flow rate; DLCO /VA, Carbon monoxide diffusion capacity/alveolar volume; RV, Residual volume; TLC, total lung capacity.

REFERENCES

1- Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. *Am J Respir Crit Care Med*. 2017;195(5):557-582.

2- Falk JA, Kadiev S, Criner GJ, Scharf SM, Minai OA, Diaz P. Cardiac disease in chronic obstructive pulmonary disease. *Proc Am Thorac Soc*. 2008;5(4):543-548.

3- Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. *Int J Chron Obstruct Pulmon Dis*. 2009;4:337-349.

4- Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. *Chest*. 2005;128(4):2068-2075.

5- Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. *Proc Am Thorac Soc*. 2005;2(1):8-11.

6- Shimoda LA, Polak J. Hypoxia. 4. Hypoxia and ion channel function. *Am J Physiol Cell Physiol*. 2011;300(5):C951-C967.

7- Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. *J Am Coll Cardiol*. 2006;47(2):362-367.

8- Sievi NA, Clarenbach CF, Camen G, Rossi VA, van Gestel AJ, Kohler M. High prevalence of altered cardiac repolarization in patients with COPD. *BMC Pulm Med*. 2014;14:55.

9- Zhang ZM, Prineas RJ, Case D, Soliman EZ, Rautaharju PM; ARIC Research Group. Comparison of the prognostic significance of the electrocardiographic QRS/T angles in predicting incident coronary heart disease and total mortality (from the atherosclerosis risk in communities study). *Am J Cardiol*. 2007;100(5):844-849.

10- Colluoglu T, Tanriverdi Z, Unal B, Ozcan EE, Dursun H, Kaya D. The role of baseline and post-procedural frontal plane QRS-T angles for cardiac risk assessment in patients with acute STEMI. *Ann Noninvasive Electrocardiol*. 2018;23(5):e12558.

11- Oehler A, Feldman T, Henrikson CA, Tereshchenko LG. QRS-T angle: a review. *Ann Noninvasive Electrocardiol*. 2014;19(6):534-542.

12- Standardization of Spirometry, 1994 Update. American Thoracic Society. *Am J Respir Crit Care Med*. 1995;152(3):1107-1136.

13- Zhang ZM, Rautaharju PM, Prineas RJ, Tereshchenko L, Soliman EZ. Electrocardiographic QRS-T angle and the risk of incident silent myocardial infarction in the Atherosclerosis Risk in Communities study. *J Electrocardiol*. 2017;50(5):661-666.

14- Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: cause, effects, and disease progression. *Int J Chron Obstruct Pulmon Dis*. 2011;6:199-208.

15- Kim V, Benditt JO, Wise RA, Sharafkhaneh A. Oxygen therapy in chronic obstructive pulmonary disease. *Proc Am Thorac Soc*. 2008;5(4):513-518.

16- Sievi NA, Clarenbach CF, Kohler M. Chronic Obstructive Pulmonary Disease and Cardiac Repolarization: Data from a Randomized Controlled Trial. *Respiration*. 2016;91(4):288-295.

17- Warnier MJ, Rutten FH, Numans ME, et al. Electrocardiographic characteristics of patients with chronic obstructive pulmonary disease. *COPD*. 2013;10(1):62-71.

18- Castro Hevia J, Antzelevitch C, Tornés Bárzaga F, et al. Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. *J Am Coll Cardiol*. 2006;47(9):1828-1834.

19- Glancy JM, Weston PJ, Bhullar HK, Garratt CJ, Woods KL, de Bono DP. Reproducibility and automatic measurement of QT dispersion. *Eur Heart J*. 1996;17(7):1035-1039.

20- Tanriverdi Z, Unal B, Eyuboglu M, Bingol Tanriverdi T, Nurdag A, Demirbag R. The importance of frontal QRS-T angle for predicting non-dipper status in hypertensive patients without left ventricular hypertrophy. *Clin Exp Hypertens*. 2018;40(4):318-323.

21- ildiz P, Tükek T, Akkaya V, et al. Ventricular arrhythmias in patients with COPD are associated with QT dispersion. *Chest*. 2002;122(6):2055-2061.

22- Zulli R, Donati P, Nicosia F, et al. Increased QT dispersion: a negative prognostic finding in chronic obstructive pulmonary disease. *Intern Emerg Med*. 2006;1(4):279-286.

23- Sarubbi B, Esposito V, Ducceschi V, et al. Effect of blood gas derangement on QTc dispersion in severe chronic obstructive pulmonary disease: evidence of an electropathy?. *Int J Cardiol*. 1997;58(3):287-292.

24- Gungor M, Celik M, Yalcinkaya E, et al. The Value of Frontal Planar QRS-T Angle in Patients without Angiographically Apparent Atherosclerosis. *Med Princ Pract*. 2017;26(2):125-131.

25- Chen J, Lin Y, Yu J, et al. Changes of Virtual Planar QRS and T Vectors Derived from Holter in the Populations with and without Diabetes Mellitus. *Ann Noninvasive Electrocardiol*. 2016;21(1):69-81.